The global Typhoid Fever Vaccines Market is estimated to be valued at US$ 454.2 Bn in 2024 and is expected to exhibit a CAGR of 14% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.
Typhoid fever vaccines help in prevention of typhoid fever which is a life-threatening illness caused by Salmonella Typhi bacteria. The symptoms include sustained high fever, weakness, stomach pains, headache, loss of appetite, etc. The vaccines are either oral (live attenuated typhoid vaccines) or injectable (inactivated typhoid vaccines) and provide protection for 3-5 years. The rising burden of typhoid fever cases globally, especially in developing regions is driving the demand for effective prevention through vaccination programs.
Market key trends:
The rising typhoid fever cases globally is one of the major drivers of typhoid vaccines market growth. According to WHO, there are over 11 million cases of typhoid fever and 116,000 deaths occurring annually worldwide. The prevalence is high in developing regions like South Asia, Southeast Asia and sub-Saharan Africa due to lack of access to clean water and sanitation. The increasing cases is prompting governments and public health organizations to scale up routine vaccination programs which is helping increase the adoption of typhoid vaccines.
Strength: Typhoid fever vaccines show high efficacy in clinical trials thus have a proven track record. These vaccines have high immunogenicity and provide long term protection up to 3-5 years with a single dose.
Weakness: The requirement of cold chain during transportation and storage increases the logistical challenges and costs involved in last mile delivery and access in remote areas. Limited availability of conjugate vaccines globally.
Opportunity: Rising awareness about typhoid prevention through vaccination programs globally especially in low and middle income countries presents an opportunity. Growing government support and funding towards public health immunization programs in these regions.
Threats: Relatively high pricing of conjugate typhoid vaccines compared to traditional viPS vaccines impacts large scale adoption and sustainable vaccination programs. Threat of antimicrobial resistance developing against first line antibiotics used for typhoid treatment.
The global Typhoid Fever Vaccines market is expected to witness high growth at a CAGR of 14% during the forecast period of 2024 to 2031.
Regional analysis: The Asia Pacific region currently accounts for the largest share of the global typhoid fever vaccines market. Countries like India, Pakistan and China have the highest disease incidence globally and ongoing government supported public immunization programs will drive vaccine demand. Several developing countries in sub-Saharan Africa are expected to emerge as high growth regional markets through 2031 due to rising awareness and funding support towards typhoid control.
Key players operating in the typhoid fever vaccines market are Linde Plc, Air Liquide, Engie, Uniper Se, Air Products Inc, Clean Hydrogen System, Cummins Inc., Toshiba Energy Systems & Solutions Corporation, Nel Asa, and Sgh2 Energy.